Kura Oncology Inc (KURA)
10.80
+0.74
(+7.36%)
USD |
NASDAQ |
Nov 22, 16:00
10.80
0.00 (0.00%)
After-Hours: 20:00
Kura Oncology Research and Development Expense (Quarterly): 41.70M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 41.70M |
| June 30, 2024 | 39.73M |
| March 31, 2024 | 36.27M |
| December 31, 2023 | 32.53M |
| September 30, 2023 | 29.33M |
| June 30, 2023 | 28.18M |
| March 31, 2023 | 25.19M |
| December 31, 2022 | 22.67M |
| September 30, 2022 | 24.97M |
| June 30, 2022 | 24.26M |
| March 31, 2022 | 20.91M |
| December 31, 2021 | 20.96M |
| September 30, 2021 | 22.37M |
| June 30, 2021 | 21.07M |
| March 31, 2021 | 20.32M |
| December 31, 2020 | 17.52M |
| September 30, 2020 | 16.60M |
| June 30, 2020 | 13.70M |
| March 31, 2020 | 12.58M |
| December 31, 2019 | 13.46M |
| Date | Value |
|---|---|
| September 30, 2019 | 12.54M |
| June 30, 2019 | 11.44M |
| March 31, 2019 | 10.38M |
| December 31, 2018 | 12.08M |
| September 30, 2018 | 11.66M |
| June 30, 2018 | 11.48M |
| March 31, 2018 | 11.57M |
| December 31, 2017 | 8.119M |
| September 30, 2017 | 7.142M |
| June 30, 2017 | 5.652M |
| March 31, 2017 | 5.513M |
| December 31, 2016 | 5.503M |
| September 30, 2016 | 5.316M |
| June 30, 2016 | 4.936M |
| March 31, 2016 | 4.649M |
| December 31, 2015 | 5.113M |
| September 30, 2015 | 4.635M |
| June 30, 2015 | 4.401M |
| March 31, 2015 | 3.628M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
12.58M
Minimum
Mar 2020
41.70M
Maximum
Sep 2024
24.22M
Average
22.52M
Median
Research and Development Expense (Quarterly) Benchmarks
| Halozyme Therapeutics Inc | 18.46M |
| AIM ImmunoTech Inc | 1.437M |
| Perspective Therapeutics Inc | 12.03M |
| Protalix BioTherapeutics Inc | 2.998M |
| Armata Pharmaceuticals Inc | 9.485M |